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Efficient processing of information by the central nervous system (CNS) represents an important evolutionary
advantage. Thus, homeostatic mechanisms have developed that provide appropriate circumstances for neuronal
signaling, including a highly controlled and stable microenvironment. To provide such a milieu for neurons,
extracellular fluids of the CNS are separated from the changeable environment of blood at three major interfaces:
at the brain capillaries by the blood-brain barrier (BBB), which is localized at the level of the endothelial cells and
separates brain interstitial fluid (ISF) from blood; at the epithelial layer of four choroid plexuses, the blood-
cerebrospinal fluid (CSF) barrier (BCSFB), which separates CSF from the CP ISF, and at the arachnoid barrier. The
two barriers that represent the largest interface between blood and brain extracellular fluids, the BBB and the
BCSFB, prevent the free paracellular diffusion of polar molecules by complex morphological features, including
tight junctions (TJs) that interconnect the endothelial and epithelial cells, respectively. The first part of this review
focuses on the molecular biology of TJs and adherens junctions in the brain capillary endothelial cells and in the
CP epithelial cells. However, normal function of the CNS depends on a constant supply of essential molecules, like
glucose and amino acids from the blood, exchange of electrolytes between brain extracellular fluids and blood, as
well as on efficient removal of metabolic waste products and excess neurotransmitters from the brain ISF.
Therefore, a number of specific transport proteins are expressed in brain capillary endothelial cells and CP epithelial
cells that provide transport of nutrients and ions into the CNS and removal of waste products and ions from the
CSF. The second part of this review concentrates on the molecular biology of various solute carrier (SLC) transport
proteins at those two barriers and underlines differences in their expression between the two barriers. Also, many
blood-borne molecules and xenobiotics can diffuse into brain ISF and then into neuronal membranes due to their
physicochemical properties. Entry of these compounds could be detrimental for neural transmission and signalling.
Thus, BBB and BCSFB express transport proteins that actively restrict entry of lipophilic and amphipathic substances
from blood and/or remove those molecules from the brain extracellular fluids. The third part of this review
concentrates on the molecular biology of ATP-binding cassette (ABC)-transporters and those SLC transporters that
are involved in efflux transport of xenobiotics, their expression at the BBB and BCSFB and differences in expression
in the two major blood-brain interfaces. In addition, transport and diffusion of ions by the BBB and CP epithelium
are involved in the formation of fluid, the ISF and CSF, respectively, so the last part of this review discusses
molecular biology of ion transporters/exchangers and ion channels in the brain endothelial and CP epithelial cells.
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Introduction
A constant and well-controlled composition of the extra-
cellular fluid in the central nervous system (CNS) is essen-
tial for efficient neuronal processing. Invertebrate nervous
systems, which are far less complex than the mammalian
brain, are protected from fluctuations in composition of
body fluids by a barrier that is formed by glial cells and
this arrangement also applies to some ancestral verte-
brates. With the CNS becoming more complex during
evolution, an endothelial barrier appeared, giving a strong
selective advantage. Consequently, all existing vertebrates,
except for a few fish species, have endothelial blood-brain
barriers (BBB).
The BBB and the blood-cerebrospinal fluid barrier
(BCSFB) are formed by brain endothelial cells (BECs)
and choroid plexus (CP) epithelial cells, respectively.
The BBB and the BCSFB are not only anatomical bar-
riers, but also dynamic tissues that express multiple
transporters, receptors and enzymes. Brain capillaries
are closely associated with perivascular astrocytic end-
feet, pericytes and microglia that influence BBB perme-
ability and, together with brain endothelial cells, consti-
tute a “neurovascular unit”.
The two main functions of these barriers are to
impede free diffusion between brain fluids and blood
and to provide transport processes for essential nutri-
ents, ions and metabolic waste products. Hence, the aim
of this review is to address similarities and differences in
the molecular biology of cellular junctions, solute carrier
transporters, ATP-binding cassette transporters and ion
transporters at the BBB and the BCSFB.
Morphology of the BBB and BCSFB
Although there are several similar features between the
blood-brain barrier (BBB) and the blood-cerebrospinal
fluid barrier (BCSFB), it should be kept in mind that the
cellular basis of these two structures as well as their pri-
mary functions differ: BBB is located in brain capillaries
and, thus, it is an endothelial structure with its main
role to protect the brain from physiological fluctuations
in plasma concentrations of various solutes and from
blood-borne substances that could interfere with neuro-
transmission, but at the same time to provide mechan-
isms for exchange of nutrients, metabolic waste
products, signaling molecules and ions between the
blood and the brain ISF. In contrast to this, the BCSFB
is created by a layer of a modified cuboidal epithelium,
the CP, that secretes cerebrospinal fluid (CSF) and this
process could be considered as main function of this
epithelium. The differences in principal function are
related to differences in morphology and molecular
biology.
Brain capillaries express complex morphology that
provide the restrictive characteristics of the endothelial
layer with regard to diffusion of solutes; this is an essen-
tial feature to protect the brain from unwanted solutes
from blood with tight junctions (Tjs) that interconnect
adjacent endothelial cells and occlude the paracellular
spaces. In addition, BECs show low pinocytotic activity
and the endothelium is further secluded by a layer of
astrocytic end feet and pericytes on the brain side that
place additional restrictions on permeability. Thus, the
BBB in vivo provides high resistance to movement of
ions, with transendothelial electrical resistance (TEER)
being in the range of 1500 Ω cm2 (pial vessels), which is
quite high when compared to TEER of 3-33 Ω cm2 in
other tissues [1]. The total capillary surface area in the
brain is about 100-150 cm2 g-1 [2], which when esti-
mated for the whole brain approximates 20 m2 [3], sug-
gesting that the BBB can be considered as a large and
thin membrane, providing ideal conditions for exchange
processes between blood and brain interstitial fluid
(ISF). When considering the total area available for
exchange, it should be noted that brain capillaries are
perfused all the time, but they shift to high blood flow
with an increase in cerebral blood flow (CBF), or to low
blood flow with a decrease in CBF [4].
Choroid plexuses are villous structures floating in the
CSF and attached to the ventricular ependyma by a
stalk. The ependyma is continuous with the epithelial
layer of the CP which is composed of a single layer of
cells filled with mitochondria and joined together by
tight TJs (Figure 1) [5]. The TEER offered by these TJs
cannot be measured in vivo in most animals. However,
in vitro measurements using the single-sided fourth ven-
tricle CP of the bull frog maintained in an Ussing cham-
ber suggested values of about 150 Ω cm2 [6], much less
than the resistance of the BBB. The low value of TEER
would suggest that the CPs fall into the class of leaky
epithelia, similar to some segments of the kidney and
gut, which form an isotonic fluid and do not generate
steep transepithelial concentration gradients across the
tissues [7]. These leaky epithelia can secrete large
volumes of fluid but use relatively little energy for this
process. CP epithelial cells posses a dense apical coat of
microvilli, while kinocilia are rarely found; in contrast to
this, the apical surface of ventricular ependymal cells
demonstrates a large number of kinocilia [8], with rare
microvilli of variable size. Between the lateral walls of
the CP epithelial cells are complex interdigitations parti-
cularly apparent close to the blood side of the tissue lay-
ing on a basal lamina that demarcate the inner stroma
of a highly vascularized connective tissue; these interdi-
gitations expand the surface area of the CP [9].
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Molecular biology of cell junctions at the BBB and
BCSFB
Brain endothelial cells (BECs) and CP epithelial (CPE)
cells are connected at a junctional complex by the TJ
and adherens junctions (AJ) [10]. BECs also express gap
junctions but their functional significance is not clear.
All TJ and AJ are composed of transmembrane proteins
and cytoplasmic plaque proteins; plaque proteins cluster
integral TJ proteins and form a platform for interaction
with scaffolding and signaling proteins. In addition, a
circumferential actin belt that encircles each endothe-
lial/epithelial cell at the level of TJs is important for for-
mation and normal function of TJs.
Protein structure of tight junctions
Transmembrane proteins of the TJ include occludin,
claudins and junctional adhesion molecules (JAM)-A, B
and C [11,12] (Figure 2). Occludin structure appears to
be essential for normal occluding function of TJs in
both BBB and BCSFB. Occludin possesses two extracel-
lular loops, four trans-membrane domains and three
cytoplasmic domains; the cytoplasmic domains include
one intracellular short turn, N-terminal domain and a
150 amino-acids long carboxyl (C-) -terminal domain
[12,13] (Figure 2). Extracellular loops provide the gate-
like structure of TJs; it is believed that second loop




Figure 1 Morphology of choroid plexus epithelium (CPE) in situ and in primary culture. A. Ultrastructure: CP from lateral ventricle of an
adult Sprague-Dawley rat. Apical membrane (CSF-facing) shows numerous microvilli (Mv) and many intracellular mitochondria (M). J refers to the
tight junction welding two cells at their apical poles. C: centriole. G and ER: Golgi apparatus and endoplasmic reticulum. Nucleus (Nu) is oval and
has a nucleolus. Arrowheads point to basal lamina at the plasma face of the epithelial cell; the basal lamina separates the CPE above from the
interstitial fluid below. Basal labyrinth (BL) is the intertwining of basolateral membranes of adjacent cells. Choroidal morphology resembles
proximal tubule, consistent with both cell types rapidly turning over fluid. Scale bar = 2 μm, reproduced from [248] with permission. B. Phase-
contrast micrographs of 8d-old sheep CPE cells cultured on laminin-coated filters shows a typical cobblestone arrangement of polygonal cells
(scale bar 20 μm). C. Eight-day-old sheep CPE cells grown on laminin-coated filters were stained with primary antibodies against occludin and
then with FITC conjugated secondary antibodies. A continuous circumferential distribution of fluorescence consistent with the establishment of
TJs in CPEC monolayer is shown. Scale bar 20 μm. Images B and C reproduced from [257].
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domain associates with zonulla occludens proteins (ZO)
-1, ZO-2 and ZO-3 and interacts with regulatory pro-
teins, such as protein kinase C, tyrosine kinase and
phosphoinositide 3-kinase [12,15]. Both occludin and
claudins are phospho-proteins that change conformation
upon phosphorylation/dephosphorylation of the side
chain hydroxyl group, which affects interaction with
other proteins; therefore, regulatory proteins mainly
posses kinase or phosphatase activities. Dephosphoryla-
tion of occludin causes disassembly of its association
with ZO proteins. Deletion of occludin in mice results
in postnatal growth retardation, although the TJs them-
selves appear to function normally [16], which suggests
that other TJ proteins compensate for the lack of occlu-
din. Occludin deletion from embryonic stem cells did
not prevent differentiation of these cells into polarized
epithelial cells with clear TJs [17]. The N-terminal part
of occludin has an important role in a TJ assembly; this
activity was revealed by an experiment in which abnor-
mal occludin that lacks N-terminal domain caused a
damaging effect on the TJ function of endothelial cell
monolayers in vitro. Those monolayers failed to develop
high TEER and developed increased paracellular diffu-
sion of small polar molecules [18]. Occludin is also sub-
ject to endocytic recycling with two proteins associated
to TJs, a member of the Rab family G-proteins, Rab13,
and a Rab13-binding protein, MICAL-L2 (molecule
interacting with CasL-like 2) mediating the specific
endocytic recycling of occludin (but not other mem-
brane proteins, like transferrin receptor), which is
important for maintenance of functional TJs [19].
A study has revealed that in Alzheimer’s disease (AD)
and in vascular dementia there were significantly more
occludin-positive astrocytes and oligodendrocytes in the
frontal white matter than in age-matched controls [20],
which may indicate autophagy of TJ proteins by the sur-
rounding glial cells.
Claudins are the principal barrier-forming proteins,
which include a multigene family consisting of at least
24 members in mammals and are an essential structural
Figure 2 Schematic representation of tight junctions between two adjacent cells. In general, TJs at the BBB and in the CP epithelium are
similar, but they express different claudins (that are not shown in this figure). This is probably an important structural difference underlying the
lower values of TEER across CP epithelium compared to TEER values across the brain endothelium.
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component of TJ strands. All claudins show the same
structural pattern: four membrane-spanning regions,
two extracellular loops and two cytoplasmic domains, a
short N-terminal sequence and a long C-terminal
sequence [21] (Figure 2). Two neighboring claudins
from two adjacent cells form TJ strands through homo-
philic claudin-claudin interactions [22]. Extracellular
loops determine paracellular charge selectivity, so each
type of claudin regulates the diffusion of a group of
molecules of a certain size. Deletion of claudin 5 in
mice showed detrimental effects on the brain causing
early death; those effects were due to a size-selective
loosening of the BBB for molecules with MW<800 Da
[23]. The claudin C-terminus binds cytoplasmic pro-
teins, particularly ZO-1, ZO-2, and ZO-3 [24] (Figure
2). Proper interaction of claudins is essential to selec-
tively limit paracellular ion movement, an action which
produces the high TEER of the BBB. It appears that the
differences in claudin content between the two barriers
play an important role in the observed differences in
TEERs between the BBB and the BCSFB [25,26]: clau-
dins 3, 5, 12 and probably 1 are present at the BBB
[10,23], while claudin 1, 2, 3 and 11 are expressed in the
CP epithelium [27]. It was initially believed that claudin-
1 was the most abundant TJ protein in the CPE and a
marker of CP TJs [27]; this was later realized to be an
artifact due to a cross-reaction of the anti-claudin-1
antibodies with claudin-3; it appears that claudin-3 is
the most abundant claudin in CPE [28].
It was known from Goldman’s second experiment [29]
that the lining of the ventricular walls, which consists of
a layer of ependymal cells, does not restrict diffusion of
solutes. The molecular basis for this is that ependymal
cells in mammals do not express TJs [30]. However,
complex TJs were described in some fish and amphibia
[31,32]. Also, it was reported in mammalian brain dur-
ing embryonic development that the ependymal cell
layer forms cellular junctions similar to TJs and provides
this layer with barrier properties [33]. This might indi-
cate that disappearance of this CSF-brain barrier could
be related to the development of the more effective
epithelial BCSFB in adult mammals.
JAMs A,-B and C are members of the immunoglobu-
lin superfamily that have a membrane-spanning domain,
an extracellular domain, an extracellular N-terminus,
and a cytoplasmic C-terminus [34] (Figure 2). JAMs are
expressed at the intracellular junctions of BECs and
CPEs and have different patterns of homophilic and het-
erophilic interactions with JAM molecules on the adja-
cent cell, forming dimers that are part of the tight
junction structure [35]. The short C terminal tail con-
tains a domain which mediates interactions with ZO-1,
cingulin, junction-associated protein AF6, tight-junc-
tion-associated protein antigen 7H6 and scaffold
proteins [36] and also includes phosphorylation sites
that may serve as substrates for protein kinase C (PKC)
[37]. It is believed that JAMs are involved in the locali-
zation of ZO-1 and occludin in TJ complexes [34].
Transmembrane TJ proteins are linked to the cytoskele-
ton by scaffolding ZO proteins 1, 2 and 3 in BECs and
in CPE [10,30]. These proteins belong to a family of
membrane-associated guanylate kinase proteins. ZO
proteins provide the cytoskeletal anchorage for the TJ
proteins and are also involved in control of spatial dis-
tribution of claudins. Cingulin is a myosin-like protein
that binds preferentially to ZO proteins at the globular
head, to other cingulin molecules at the tail and to
actin. Actin has known binding sites on all of the ZO
proteins, on claudin, occludin and cingulin [38].
A study on rat BBB that used serial analysis of gene
expression (SAGE) provided a comprehensive gene
expression profile of rat BECs from freshly-collected
brain microvasculature and has revealed that the SAGE
tag for claudin 5 was 16th of the 50 most abundant tags
enriched in BECs [39] with a relative abundance in rat
BEC SAGE catalog 52 tags/100.000. Other TJ protein
transcripts were less abundant: claudin 11 (18/100.000),
ZO-2 (11/100.000) and ZO-1 (3/100.000) and they were
not among the 50 most abundant tags enriched in BECs
[39].
Through interactions with other proteins and/or as a
consequence of cell signaling, TJs in the brain are
dynamic structures; spatial distributions of proteins can
be changed under various circumstances. Effects of sig-
naling on TJ expression and integrity have been studied
for pathophysiological conditions, including cerebral
ischemia in vivo, conditions that mimic ischemia in vitro
and inflammation. Claudin 5 expression was reduced
and localization in BECs altered by hypoxia in vitro;
changes were accompanied by a decrease in TEER [40].
A decrease in occludin and ZO-1 expression in BECs
after cerebral embolism has been reported [41] and
localization of occludin, ZO-1, and ZO-2 proteins was
altered after hypoxia in vitro [42]. In addition, ZO-1 and
ZO-2 shifted to the nucleus during hypoxia in vitro, a
relocation that was accompanied by increased paracellu-
lar permeability [43]. Recent studies have also revealed
an important role of transforming growth factor (TGF)-
b-signaling in expression of TJ proteins claudin-5, occlu-
din and ZO-1 [44]. These studies showed that peripheral
inflammatory pain caused a reduction in serum TGF-b1
and protein expression of the TGF-b receptor, activin
receptor-like kinase-5 (ALK5), in the brain; changes
were accompanied by increased expression of TJ pro-
teins and increased paracellular permeability of the BBB
[44]. The same effects were produced by pharmacologi-
cal inhibition of ALK5, which indicated that TGF-b/
ALK5 signaling was involved in the regulation of TJ
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protein expression and/or their spatial distribution [44].
Also, oxidative stress produced during hypoxia and
reoxygenation mediated an increase in BBB paracellular
permeability, probably because of alterations in the loca-
lization of occludin, with movement of occludin away
from the TJ [45]. Protein kinase C (PKC) is involved in
control of TJ expression in BECs and it was shown that
PKC isoenzyme nPKC-theta signaling mediated TJ pro-
tein rearrangement, resulting in increased BBB paracel-
lular permeability [46]. A study on cell culture - induced
changes in the blood-brain barrier transcriptome in
mice by qPCR has revealed that there was a dramatic
drop in the relative amount of mRNA for claudin 5 and
occludin in single cultured cells, in cells co-cultured
with astrocytes and in immortalized cell line, when com-
pared to non-cultured and freshly isolated mouse BECs
[47]. This finding could explain fairly low TEER values
in BEC cell cultures, when compared to TEER of BECs
in vivo.
Adherens Junctions
Adherens junctions (AJs) are specialized cell-cell junc-
tions that are formed by cadherins and associated pro-
teins into which actin filaments are inserted. Optimal
function of cadherins requires association of their C ter-
minus with catenins; cadherins bind directly to b-cate-
nin and to p120 catenin, which can bind to a-catenin, a
protein that in turn binds actin [48]. In endothelial cells,
vascular endothelial (VE) cadherin is present [35,49];
however, a study has shown that barrier-forming
endothelium (i.e. BECs) and barrier-forming epithelium
(i.e. CPE) mainly expressed cadherin-10, while the
expression of VE cadherin was scarce [50]. On the other
hand, brain microvessels that do not have BBB proper-
ties (i.e. in the circumventricular organs and CP capil-
laries) expressed only VE-cadherin and did not express
cadherin-10 [50]. Also, in the microvessels of glioblas-
toma multiforme tumors, which lose BBB properties,
VE-cadherin was expressed instead of cadherin-10 [50].
These findings suggest that cadherin-10 has an impor-
tant role in the development and maintenance of the
BBB and the BCSFB. Cadherins regulate endothelial
functions by direct activation of phosphoinositide 3-
kinase, a signaling system that has a role in organization
of the cytoskeleton and forms complexes with the vas-
cular endothelial growth factor (VEGF) receptor 2.
Thus, cadherin-mediated signaling is important for
endothelial cell layer integrity and for the spatial organi-
zation of new vessels [51]. At least four catenins, b, a, c
and p120 are expressed at the BBB, with b-catenin link-
ing the cadherin to a-catenin which binds the complex
to the actin network of the cell skeleton [49]. However,
a study has challenged this view, since it was unable to
confirm actin binding to a preformed E-cadherin-b-
catenin-a-catenin complex [52]. As mentioned above,
CPE expresses cadherin-10 while CP capillaries express
VE-cadherin [50]. Only two catenins, a and b, have
been detected in the CP epithelium so far, with a-cate-
nin binding to the actin network [52].
In summary, BECs and CP epithelium show many
similarities in the organization of Ts and AJs; the main
difference is that the CPE provides a barrier that offers
lower TEER values and is less restrictive than the BBB.
The molecular organization underlying that difference is
probably related to expression of different claudins,
since those proteins play an important role in barrier
size-selectivity and selectivity to paracellular movement
of ions.
Molecular biology of transport processes between
blood and brain extracellular fluids
TJs restrict paracellular diffusion across cellular layers.
Thus, hydrophilic molecules cannot readily enter brain
ISF or CSF by simple diffusion and must be transferred
across the layer by transcellular routes. On the other
hand, lipid soluble non-polar molecules can easily dif-
fuse into lipid bilayers and thus affect the composition
of cellular membranes. The later process could have a
detrimental impact on brain function. Thus, the BBB
and the BCSFB have, in general, a similar functional
organization with regard to transport of molecules: they
express various proteins in their membranes that either
use carrier-mediated transcellular transport of solutes,
maintaining optimal composition of the brain ISF, or
use ATP-driven efflux of lipophilic molecules, the latter
process having an important role in maintenance of
lipid bilayers in brain cells [53].
Proteins that mediate transport of solutes not directly
coupled to ATP hydrolysis belong to a superfamily of
solute carriers (SLC); this family includes facilitated
transporters, ion-coupled transporters and exchangers
that do not require ATP. They facilitate membrane
transport of monosaccharides [54], amino-acids [55],
monocarboxylic acids [56], vitamins [57], nucleosides
[58,59], purine [60] and pyrimidine [61] bases, ions and
amphipathic molecules (organic anions and organic
cations). The second superfamily consists of ATP-bind-
ing cassette (ABC) proteins that directly couple efflux
transport of molecules from a lipid bilayer against the
concentration gradient to ATP hydrolysis [53]. Due to
the presence of ABC-transporters, a large number of
solutes and xenobiotics have a much lower transfer rate
into the CNS than might be expected from their lipo-
philicity, which is expressed as logD octanol/buffer par-
tition coefficient at pH 7.4.
There are large dissimilarities between the BBB and
the BCSF in regard to expression of SLCs and ABC
transporters. Also, some of these transport proteins are
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expressed in both membranes of the two barriers, in the
one that faces brain fluids and in the one that faces
blood/CP ISF; other transport proteins are inserted into
either the luminal or abluminal membrane only.
Glucose transporters
Glucose is the principal energy source for mammalian
brain and a continuous supply of this substrate is essen-
tial to maintain normal cerebral function [62]. The
brain rapidly catabolizes glucose, which creates a down-
hill gradient for this hexose from blood towards the
brain ISF and glucose transport into brain is mediated
by facilitative glucose transporter proteins. Delivery of
glucose from the blood to the brain requires transport
across the endothelial cells of the blood-brain barrier
and across the plasma membranes of neurons and glia.
There are also several lines of evidences indicating
metabolic coupling between astrocytes and neurons,
whereby glucose is used and lactate is released into the
ISF by the astrocytes [63,64]. Lactate is then taken up
by neurons, where it serves as an important fuel. Astro-
cytes appear to form the first cellular barrier that glu-
cose faces when entering the brain and they are ideally
located to provide coupling between neuronal activity
and glucose uptake.
Several isoforms of equilibrative glucose transporters,
GLUT, have been identified in the brain, which included
GLUT1 (Human Genome Organization, HUGO, name
SLC2A1) [65], 3 (SLC2A3) [66] and 8 (SLC2A8) [67].
GLUT 1 is a ubiquitous glucose transporter in mamma-
lian cells and it is abundant in the brain; also it is exclu-
sively expressed at the BBB, especially at its abluminal
membrane and in CPE cells (Figure 3A, B) [62]. Thus,
not surprisingly, a rat blood-brain barrier transcriptome
study revealed that GLUT1 tag was within 15 of the
most abundant tags enriched in rat brain microvessels,
together with tags that corresponded to mRNA encod-
ing P-glycoprotein (P-gp), transferrin receptor and the
thyroid hormone transporter Oatp1c1. It was also the
most abundant tag when compared to tags identifying
other solute-carrier family members, indicating the
importance of glucose transport at the BBB for brain
homeostasis [39]. With regard to this study, it should be
noted that at least several tags out of those top-15 were
in fact associated with genes expressed in reticulocytes
(like hemoglobin b chain), which was probably due to
contamination of brain microvessels with red blood cells
[39]. GLUT1 has molecular weight (MW) which can
range between 45 kDa (smaller MW species) to 55 KDa
(larger MW species) [68].
Most parameters for GLUT1 kinetics have been deter-
mined in red blood cells and Xenopus oocytes at sub-
physiological temperatures (20°C) using zero-trans flux
estimation that revealed Km for glucose 1.6-4.6 mM and
16.9-26.2 mM (equal exchange method) [69]. However,
a recent study using a multicompartmental data analysis
on BECs in culture revealed a Km of 1.5-3.5 mM [70].
The larger MW species are present in microvessels [71],
the smaller species are present in neurons and glial cells
and the intermediate species in the CPE [72]. The differ-
ent molecular weights are associated with differences in
N-linked glycosylation and could also affect affinity for
glucose. The other functional effects of different glycosy-
lation states are not clear although there is evidence
suggesting that they are involved in GLUT1 trafficking
and substrate affinity.
GLUT 1 expression is controlled by the hypoxia-indu-
cible factor 1 (HIF-1), which is a key regulator in cellu-
lar adaptations to a decrease in partial pressure of
oxygen [73]. HIF-1a protein is unstable under normoxic
conditions and is constantly degraded by activity of pro-
lyl hydroxylases [74]. During hypoxia, HIF-1a protein is
stabilized by a decrease in activity of prolyl hydroxylases,
binds to its binding partner HIF-1b, and translocates to
the nucleus to bind to hypoxia-responsive cis-elements
[75]. Through this mechanism, HIF-1 activates multiple
genes involved in angiogenesis and metabolism, includ-
ing those genes that regulate glucose uptake and utiliza-
tion [73]. It has been shown that transient brain
ischemia causes an increase in HIF-1 “downstream”
genes, including GLUT1 expression [76]. However, it is
not clear if this signaling pathway plays any role in con-
trolling GLUT1 expression under normoxic conditions.
A recent study revealed that in BECs in primary culture,
sodium-glucose cotransporter (SGLT) - mediated glu-
cose uptake was induced during ischemia-like conditions
in vitro and was also induced during permanent middle
cerebral artery occlusion in vivo [77].
Importance of GLUT1 for the brain homeostasis can
be observed in a rare genetic disease known as GLUT1
deficiency syndrome [78] that is caused by heterozygous
mutations of the GLUT1 gene and is inherited as an
autosomal recessive trait [79]. In this condition brain
development and function are severely affected, with
microcephaly and number of other CNS symptoms/
signs, including developmental delay, intellectual disabil-
ity, spasticity, ataxia, dysarthria and myoclonus [80,81].
Similar findings were observed after heterozygous muta-
tions of the GLUT1 gene in mice (GLUT1+/- mice), a
condition that was associated with reduced expression
of GLUT1 in BECs. Those animals showed signs similar
to GLUT1-deficient patients, including microcephaly,
seizures, incoordination, and spasticity [82].
It has been also postulated that GLUT 1 downregula-
tion may be linked to neuronal deficits in Alzheimer
disease (AD). Mooradian et al. in 1993 showed that cer-
ebral cortices from AD patients contained less GLUT1
protein than controls [83]. It remains unclear whether
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reduced expression of GLUT1 in cortical samples of AD
patients was caused by reduced demands of affected tis-
sue or whether reduced glucose availability could be one
of the causes for neuronal degeneration. Regional glu-
cose uptake studies have demonstrated that individuals
diagnosed with aging-associated cognitive decline had
reduced glucose uptake in several cortical regions [84].
Mosconi et al. [85] suggested that reductions of glucose
uptake by the hippocampus can predict cognitive
decline associated to AD before clinical diagnosis.
However, given the kinetic properties of GLUT1 [70],
even if GLUT1 expression is reduced at the BBB, it
should be associated with sufficient downhill transport
of glucose to provide enough fuel to support neuronal
activity.
It appears that GLUT1 expression at the BBB is also
influenced by astrocytes and other glial cells, so that when
the brain needs more glucose, GLUT1 expression in the
BECs becomes upregulated. Regina et al. [86] found that
treatment with conditioned medium obtained from
A B
Figure 3 Solute carrier transporters (SLCs) in the BECs (A) and in the CP epithelial cells (B). Only SLC involved in transport of
monosaccharides, amino-acids, monocarboxylic acids and peptides are shown. A. A proposed model of SLCs distribution in BECs. A question
mark with MCT8 transporter indicates that in BECs this transporter is detected at the transcript level, but its cellular localization is not clear. Also,
there are conflicting data on LAT2 expression, also indicated by a question mark. Members of the peptide transporters family (PTR) are not
present in BECs. B. A proposed model of SLCs distribution in CPE cells. A question mark indicates that there is conflicting data about presence of
SGLT1 in CPE cells. Symbols in superscript indicate: a -GLUT1 is present in the apical membrane of the CPE cells, but it is much less abundant in
that membrane than in the basolateral membrane; b - System y+ was detected at the transcript level in CPE cells and functional uptake studies
indicated that it was located in the basolateral membrane; c - Uptake studies in the rat in vivo indicated that EAAT1 substrates aspartate and
glutamate were taken by CPE from CSF side by a saturable and stereospecific mechanism that did not show cross-inhibition with neutral amino
acid. However, EAAT1 is not expressed in normal CPE in humans and is expressed in dedifferentiated CPE cells in CP tumors; d-CPE cells express
MCT 1, but at much lower level than BECs and cellular localization of this isoform includes both basolateral and apical membranes. CPE cells also
express a lysosomal AA transporter LYAAT1, which is located intracellularly.
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glucose-deprived astrocytes increased endothelial GLUT1
expression and glucose uptake in rat BECs; however, no
change in GLUT1 expression was observed in endothelial
cells treated with astrocyte-conditioned medium when
astrocytes were maintained under normoxic conditions.
This indicates that hypoxic astrocytes release humoral fac-
tors that upregulate GLUT1 expression in BECs. Further
insight into a proposed mechanism was provided by Yeh
et al. [87] who found that conditioned medium from rat
C6 glioma cells under hypoxia up-regulated glucose
GLUT1 expression in rat BECs, whereas conditioned med-
ium from C6 cells under normoxia caused no significant
effect. This effect is likely to be mediated by VEGF, which
is also a HIF-1 “downstream” gene [73]; when C6 cells
were transfected with VEGF small interfering RNA that
diminishes VEGF mRNA expression, it was found that
conditioned medium from transfected cells under hypoxia
no longer up-regulated GLUT1 expression in BECs and
that a similar effect was observed when VEGF-neutralizing
antibody was added to the hypoxic conditioned medium
[87]. Interestingly, rat BECs in primary culture often
express GLUT3, a transporter that is present in neurons
but not in brain capillaries in vivo [86], which may be a
sign of dedifferentiation of BECs in culture.
Glucose in the CSF is about 50-60% of plasma glu-
cose, which creates a downhill gradient towards the
CSF. It has been shown that there was a net glucose
transfer from the fluid in CP capillaries to the CSF dur-
ing in situ perfusion of sheep CP and that this process
was Na+-independent [88].
Immunocytochemical studies revealed diffuse GLUT1
immunoreactivity in rats, mice and rabbits [89,90] with
the basolateral CPE membrane being stained more
intensively (Figure 3B). Other studies could not confirm
that GLUT3 [91] and GLUT2 (SLC2A2) [92] were pre-
sent in the CP epithelium. An immunogold electron
microscopy study has revealed very dense staining for
GLUT1 in CP capillaries, while staining of CPE was less
intense [93]. Interestingly, this study found that while
the basolateral membrane showed staining for GLUT1,
it was almost absent on the apical membrane [93], indi-
cating low expression. The high affinity hexokinase 1 is
abundant in the CPE [91], which may indicate that glu-
cose taken up by GLUT1 is used largely to satisfy the
high metabolic demands of the CPE. Reports of expres-
sion of the sodium-dependent glucose transporter 1
(SGLT1) are conflicting in the CPE (Figure 3B).
In conclusion, there is a difference between the func-
tional roles of glucose transporters in the BECs and in
the CPE; the former provides transcellular flux of glu-
cose towards brain ISF, which is vital for providing the
brain with its main fuel; the latter appears to be more
important for supplying glucose to support the CPE
metabolic demands.
Amino acid transporters
Brain requires several essential amino acids (AA) for
protein synthesis; although the rate-limiting step in
brain uptake of circulating amino acids is BBB transport
[94], under normal physiologic conditions the synthesis
of brain proteins is not rate-limited by the availability of
amino acids [95]. It was revealed that the influx of
amino acids from blood-to-brain approximates the rates
of amino acid incorporation into brain proteins [94].
Most essential AAs are neutral, with long or bulky
chains and are substrates for some of the system-L
amino acid transporters (LAT) [96]. It is believed that
LAT1 (SLC7A5) is the main AA transporter at the BBB;
immunohistochemical analyses have shown that the
LAT1 was expressed in the BECs in rats in the luminal
and abluminal membranes (Figure 3A). It has been
shown that, in fact, LAT1 activity is induced in Xenopus
oocytes by cloned cDNA from mouse encoding 4F2
light chain (4F2lc), but its trafficking and insertion into
the cell membrane depended largely on co-expression
with 4F2 heavy chain (4F2hc) as 4F2lc-4F2hc covalent
complex (which was also known as CD98 membrane
antigen) [97]. This underlines the importance of 4F2
heavy chain in bringing and inserting LAT1/4F2lc into
the plasma membrane. Human and rat 4F2hc when
inserted into membranes alone induce so-called y+ L-
like activity (sodium-independent transport for basic
amino acids, and sodium-dependent transport for neu-
tral amino acids). In contrast, transient transfection of
rat 4F2hc in Chinese hamster ovary cells results in an
increase in L-isoleucine transport with characteristics of
system L [98,99]. Thus, it appears that 4F2hc is essential
for proper function of LAT1, but this protein itself med-
iates amino-acid transport. In mouse BECs 4F2hc
mRNA was the most abundant among all AA transpor-
ters mRNAs, as revealed by qPCR [98].
However, RT-PCR data and kinetic analysis of [3H]-
leucine uptake, revealed that LAT2 (SLC7A6), which
has a lower affinity for this substrate, is also expressed
in rat BECs in culture [100]. Kinetic analysis of amino
acid transport by the brain provided data that could
indicate that both LAT1 and LAT2 show affinity for
small neutral AAs, alanine, serine and cysteine [101].
However, it should be noted that mouse BECs in pri-
mary cultures had significantly downregulated all
mRNAs encoding AA transporters, as revealed by qPCR
[47]. Some essential amino acid are cationic; these are
transported from blood into brain by a Na+-dependent
saturable carrier, system y+ (SLC7A1) that is present at
the luminal side of the BBB (Figure 3A) and expression
of y+ in BECs exceeds 38-fold expression in the whole
brain homogenate [102].
Beside LAT1, several other AA transporters are pre-
sent at the abluminal, brain ISF-facing side of the BECs
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(Figure 3A). System A (SLC38A2) (alanine preferring)
was first characterized and previous kinetic studies
showed that it actively transported small nonessential
neutral amino acids [103]. At least four other Na
+-dependent carriers exist at the abluminal membrane:
system ASC (SLC1A5) alanine, serine, and cysteine pre-
ferring, [104], system Bo+ (SLC7A3) for basic AAs [105],
system N (SLC38A5) for nitrogen rich AA (glutamine,
asparagine, and histidine) [106], and excitatory amino
acid transporters (EAAT) (SLC1A1-3), that mediate
transport of aspartate and glutamate [107]. Small AAs,
alanine and serine are transported by two Na+-depen-
dent transport systems that are located exclusively in
the abluminal membrane [105]: the system A, which is
probably the main route for Na+-dependent alanine
transport with a Km of 0.6 mM and system ASC that
also shows affinity for large neutral AA. The physiologi-
cal importance of those two transport systems is
unclear, but they may be related to AA efflux from the
brain.
The sodium-dependent system EAAT deserves atten-
tion because it permits a net removal of glutamate from
the brain. Glutamate concentration in blood is 50-100
μM [107,108]; in whole brain homogenate it exceeds 10
mM, while in the brain ISF it is normally kept below 2
μM [109]. Glutamate can exert neurotoxicity if it accu-
mulates in the brain ISF, because, through its action on
metabotropic NMDA receptors, it could lead to Ca++
overload, causing neuronal injury or death [110]. Gluta-
mate is released during neurotransmission but is nor-
mally rapidly taken up by neurons and neighboring
astrocytes. However, during cerebral ischemia and/or
hypoxia, this AA accumulates in the brain ISF, especially
in regions that are rich in glutaminergic neurons. There
are three EAATs present at the abluminal side of the
BECs, EAAT1 (SLC1A1), EAAT2 (SLC1A2), and
EAAT3 (SLC1A3) [107,110] (Figure 3A) and their action
appears to be important to prevent excitotoxicity
because they actively remove glutamate from the ISF
into the BEC cytoplasm. At the luminal side of the BBB,
glutamate is transported by facilitative glutamate trans-
porter XG
- [110]. It has been demonstrated that scaven-
ging glutamate in the blood with a glutamate-scavenging
agent oxalocaetate increased the efflux of excess gluta-
mate from the brain and reduced brain damage after
closed head injury [111].
Available data on amino acid concentrations in the
CSF is inconsistent, but it is clear that CSF to plasma
ratios are lower than 1, ranging from <0.1 for neuro-
transmitters, like glycine and glutamic acid, to > 0.1 for
small neutral AAs [112]. Early functional studies
revealed that many neutral AA as well as glutamate and
aspartate were taken across the luminal side of the CPE
by a Na+-independent mechanism [113]. It was revealed
later that the CPE expresses LAT1 [114], which could
be responsible for the observed Na+-independent AA
uptake, but expression of this transporter is less abun-
dant than expression in the BECs (Figure 3B). A second
AA transporter that is abundant in the BECs, the y+ AA
transporter, was also found to be present in the CPE at
the transcript level; however, its abundance in the CP
was less than in the BECs [102]. Previous functional
uptake studies revealed that arginine and leucine were
taken up by the blood side of the sheep CP by a sepa-
rate transport process that did not show any cross-inhi-
bition with neutral amino acids [115]. Uptake studies
have indicated that CPE expresses system N, while the
transport activity for small neutral AA (mediated by sys-
tems A and ASC) was absent [116] (Figure 3B), which
confirms finding by Preston and Segal [115] that uptake
of A and ASC substrates by isolated perfused CP was
very low. Both choroid plexus epithelium and ependy-
mal cells lining the ventricles express the lysosomal
amino acid transporter(LYAAT-1) that mediates H+ co-
transport with a stoichiometry of 1 H+/1 amino acid
[117] (Figure 3B); however its role is not very clear.
LYAAT-1 plays a role in the active efflux of amino acids
from lysosomes and in the CNS it is also abundantly
present in neurons [117].
It has been shown, using ventriculo-cisternal perfusion
in rat, that accumulation of aspartate and glutamate by
the choroid plexus from CSF side was saturable, stereo-
specific, not inhibited by neutral amino acid analogues,
and shared by both aspartate and glutamate [118]. A
recent study in humans revealed that CPE, contrary to
the BBB, does not express EAATs [119], which suggests
that it does not normally play an active role in removing
those excitatory neurotransmitters from brain extracel-
lular fluid. However, de-differentiated CP cells, seen in
CP tumors, express EAAT1; this feature distinguishes
neoplastic from normal CP and could be used as a help-
ful diagnostic tool [119].
Monocarboxylate transporters
As noted above, the CNS is an obligate glucose consu-
mer that depends almost entirely on the supply of glu-
cose from the systemic circulation. However, several
findings suggest that glial cells and neurons do not use
glucose as a fuel to the same extent: astrocytes take up
glucose that is transported across the BECs and use it
for the glycolysis, producing lactate that is released into
the ISF and subsequently taken up by surrounding neu-
rons [120]. Also, evidences suggest that neurons during
development use lactate as an important source of
energy during neuronal migration, since in vivo block-
ade of lactate transport in the brain over postnatal day
1-3 in mice induced a cytoarchitectonic disorganization
in the parietal cortex that was likely due to a
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disturbance of cortical neuronal migration and an
increased neuronal cell death [121]. Lactic acid has a
pKa of 3.9, thus it exists almost entirely as the lactate
anion at physiological pH. Both the proton and the lac-
tate or other monocarboxylate anions require a specific
transport mechanism to cross cell membranes, which is
provided by proton-linked monocarboxylate transporters
(MCTs) [122]. Fourteen MCTs have been identified so
far [123]. Four MCTs are present in the brain: MCT1,
MCT2, MCT4 and MTC8, which are selectively present
in distinct cell types and membrane domains [124].
MCT4 is expressed in astrocytes and its main role is to
export lactate produced during glycolysis into the ISF;
from there lactate is transported into neurons by MCT2
[124]. BECs express MCT1 (SLC16A1) at both luminal
and abluminal membranes and also in intracellular orga-
nelles (Figure 3A) [125] and this transporter has a fairly
high affinity for lactate when compared to other MCTs
(Km 3.5 mM, [124]). MCT8 (SLC16A2) mRNA and pro-
tein are also expressed in cerebral microvessels [126].
Human MTC8 transporter mediates transport of thyroid
hormones and the importance of transport for thyroid
hormone signaling was revealed by the discovery that
inactivating mutations in the human monocarboxylate
transporter-8 (MCT8) cause Allan-Herndon-Dudley syn-
drome, an X-linked developmental disorder character-
ized by hypotonia, spasticity, muscle weakness,
neurological problems, and cognitive impairment due to
thyroid hormone deficiency in the CNS [127]. In
humans, plasma lactate is below 1 mM under normal
physiologic conditions while in the brain ISF it is above
3 mM [64]. Under those conditions the MCT1 at the
BBB probably pays a role in lactate removal from the
brain ISF to the blood, to avoid its accumulation in the
brain. However, during starvation, when following a
ketogenic diet or under hypoxic conditions, plasma lac-
tate and ketone bodies increase so the gradient across
the BBB could change. It has been shown that diet-
induced ketosis in rats caused a substantial upregulation
of MCT1 at the BBB, associated with an increased
extraction of plasma ketone bodies by the brain [128].
Interestingly, the rat BBB transcriptome study has
revealed that a tag that identified MCT7 (Slc family 16
member 6) was the second most abundant tag in the
microvessel SAGE catalog, with abundance that was
only slightly below that of GLUT1 [39].
CPE primarily expresses MTC8, which is located on
the apical surface and it is believed to be involved in
thyroid hormone transport [126] (Figure 3B). It also
expresses MTC1, but at much lower level than BECs
and cellular localization of this isoform includes both
basolateral and apical membranes [129], while MTC2
transcripts were not found in the CPE [130].
Peptide transporters and receptors
The delivery of peptides to the brain has important phy-
siological and clinical implications, because in many
neurodegenerative diseases it has been found that the
application of various growth factors/neuroactive pep-
tides may protect neurons and/or stimulate neuronal
growth and repair and, thus, improve outcome for neu-
rological disease. Peptide-based amyloid-b (Ab)-aggrega-
tion inhibitors have been shown to decrease the
deposition of Ab in transgenic mouse models of Alzhei-
mer’s disease [131]. Also, nerve growth factor (NGF)
showed the ability to reduce neuronal degeneration in
animal models of Alzheimer’s disease [132]. In vitro and
in vivo data suggest that treatment with neurotrophic
factors such as NGF, glial cell line-derived neurotrophic
factor (GDNF), brain-derived neurotrophic factor
(BDNF) and several neurotrophins (NTs) could induce
survival of specific neuronal populations in Huntington’s
disease [133]. Treatment strategies aiming to regenerate
existing dopaminergic neurons in Parkinson’s disease by
applying GDNF, BDNF, IGF and NT-4/5 have also been
attempted [134,135].
However, blood-to-brain transfer of intact peptides
remains controversial. Peptides cannot use AA transport
systems for facilitative transport because of the existence
of the peptide bond (for a review see [136]). Even dipep-
tides that contain LNAAs do not show measurable affi-
nity for facilitative transport by LAT1 at the BBB [137].
However, there are specific transport systems that med-
iate transport of peptides. The peptide transporters that
belong to the peptide transporter (PTR) family are
solute carrier proteins (SLC15A) responsible for the
membrane transport of di- and tripeptides [138].
Another peptide transporter family (PTS), that contain
at least 9 members (PTS1-9) mediate transport of larger
peptides (more than 3 AAs in chain) and in many tis-
sues act primarily as an efflux pump, removing lipophi-
lic peptides from cellular membranes. PTR family
consists of four members, two peptide transporters
PEPT1 and 2 (SLC15A1-2) and two histidine transpor-
ters that also transport dipeptides (PHT1 and 2,
SLC15A3-4). PTRs couple substrate movement across
the membranes to movement of protons down an
inwardly-directed electrochemical proton gradient [138].
Early studies have shown that arginine vasopressin
(AVP) [139], enkephalins [140,141], delta-sleep-inducing
peptide (DSIP) [142] and luteinizing-hormone-releasing
hormone (LHRH) had a measurable volume of distribu-
tion in the guinea pig brain after in situ perfusion but
the rates of blood-brain transfer were 103-104 fold lower
than rates of carrier-mediated amino-acid transport.
Tetrapeptide tyrosine melanocyte-stimulating inhibitory
factor 1 (Tyr-MIF-1) was the first peptide shown to pass
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from blood to the brain by a saturable system [143].
Although there is no evidence so far that any of the
PTR four members, that could mediate efflux transport
of di- and tri-peptides are present in the BECs, these
cells probably express at least some PTS members
located at the abluminal side that mediate efflux trans-
port of several small peptides from the brain ISF: enke-
phalins, Tyr-MIF-1, arginine vasopressin (AVP) and
LHRH [144]. For example, pituitary adenylate cyclase-
activating polypeptide (PACAP), which has neuroprotec-
tive effects against ischemia, can pass across the BBB,
but its efflux, which is mediated by PTS-6, severely
restricts its net entry into the brain ISF. However, when
PTS-6 expression in BECs was inhibited by antisense
targeting, brain accumulation of PACAP increased sig-
nificantly [145], which indicates that the main role of
this transporter is efflux transport. Thus, it appears that
BBB transport system for peptides could be involved in
impeding blood-to-brain ISF transfer of intact peptides.
The brain delivery of peptides is further impeded by the
existence of various enzymes in BECs that modify AA
side chains or hydrolyze peptide bonds. These enzymes
include g-glutamyl transpeptidase, aromatic acid decar-
boxylase, dipeptidyl(amino)peptidase IV, and aminopep-
tidases A and N [146]. However, it has been shown that
some neuropeptides, when present in capillaries, could
be transferred to the brain ISF in intact form, like
DSIP [147].
Larger peptides and proteins that have receptors pre-
sent at the luminal side of BECs could use receptor-
mediated transcytosis to pass across the BBB and that
mechanism was revealed for insulin [148], transferrin
[149], certain cytokines [150], leptin [151,152], immuno-
globulin G [153], and insulin-like growth factor [154]. It
seems that Ab could also pass the BBB by receptor-
mediated transcytosis. This peptide (MW ~4500 Da) is
bound in plasma to several proteins, including albumin,
apolipoprotein E (apoE), apolipoprotein J (apoJ), trans-
thyretin (TTR), a2-macroglobulin (a2M) and low-den-
sity lipoprotein receptor related protein-1 (LRP1)
[155-157]. There is evidence which suggests that influx
of Ab into the brain across the BBB involves binding of
this peptide to the receptor for advanced glycation end
products (RAGE) and subsequent receptor-mediated
transcytosis [158]. Advanced glycation end products
(AGE) accumulate in the basement membrane of the
BBB and this triggers increased expression of RAGE in
the BECs, which could lead to increased blood-to-brain
transcytosis of Ab [159]. In the brain ISF, Ab is
degraded while some remains bound to apoJ, apoE and
a2M [160]. Some reports suggest that expression of
LRP1 has an important role in the prevention of Ab
accumulation in the brain by several mechanisms. One
mechanism includes binding of brain Ab to LRP1 at the
abluminal (brain ISF-facing) membrane of the BECs in
vitro, which leads to a subsequent transcytosis of Ab-
LRP1 complex [161]. Some of the Ab-apoJ complexes
from the brain ISF bind to LRP2 (also known as mega-
lin), which also triggers transcytosis of this complex and
subsequent brain-to-blood efflux of Ab [162]. Ab also
binds to LRP1 in plasma; taking into account the abun-
dance of LRP1 in plasma when compared to amount of
circulating Ab, this binding provides a peripheral ‘sink’
for plasma Ab [160]. However, a key point in this
hypothesis is challenged by in vivo findings of Ito and
colleagues [163], who revealed, using the brain efflux
index technique in mouse that simultaneous injection of
receptor-associated protein (RAP) with radiolabelled Ab
failed to cause inhibition of Ab efflux transport across
the BBB. Since RAP is a chaperon protein which inhibits
the ligand interactions with LRP1, the authors conclude
that LRP1 interaction with Ab is not essential for brain
efflux of Ab and that this efflux is LRP1 independent
[163]. This finding was challenged [160], by a group
who claim that Ito and co-workers have not performed
control experiments to determine 125I-Ab integrity prior
to its use and/or at the end of the experiment in brain
extracts.
In adsorptive endocytosis, the interaction of a glyco-
protein, or positively-charged peptide, with glycoproteins
or negatively-charged regions of the BECs causes
adsorption of the molecule to the surface of the BECs.
This in turn causes internalization of the molecule into
the BEC [164]. However, it is not clear what determines
the fate of those vesicles; they could be delivered to the
Golgi, or lysosomes, or they could move across the cyto-
plasm and fuse with the abluminal membrane [165]. An
alternative strategy to enhance peptide delivery to the
brain is modification of amino acid side chains in small
peptides (150-500 Da) to improve liposolubility (ideally
a log octanol/water partition coefficient should be 0.5-
6.0), to enable these peptides to diffuse across the BEC
membrane [166]. Although it has been proposed that
peptides with MW > 400 Da cannot cross the BBB
[167], so far there is no clear evidence that an absolute
MW cutoff point exists for crossing the BBB. However,
this strategy faces another obstacle, because with
increasing lipid solubility sequestration by liver and
binding to plasma proteins also increases, which
decreases the half-life of a peptide in plasma and
reduces availability for interaction with BECs. Also, free
diffusion is often followed by proteolytic cleavage in the
BECs or active efflux from the BECs by P-gp or PTSs
[144]. For example, blood-to-brain transport of Tyr-
MIF-1 and the enkephalins is very limited because of
the action of PTS1 in the abluminal membrane of BECs,
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which mediates efflux of those peptides [168]. Also, P-
gp mediates efflux transport of several opiate peptides
and inhibition of efflux pumps was accompanied by a
several-fold increase in peptide accumulation by the
brain [169].
Another alternative strategy is to use receptor-
mediated transcytosis through the BBB for drug delivery
to the brain. This strategy, known as a “Trojan horse”,
includes conjugation of different peptides that have very
limited delivery to the brain to monoclonal antibodies
against one of the BBB peptide receptors, like the trans-
ferrin receptor [170]; binding of the antibody to receptor
triggers endocytosis, as explained above. However, these
receptors are not brain specific and are widely expressed
in peripheral organs, a fact that limits their applicability
for brain-targeting. A recent study used phage display in
an in situ brain perfusion model to screen for peptide
ligands that bind specifically to brain endothelium [171].
Using this strategy, new peptide ligands were identified
that showed significant binding to human brain
endothelium but not to other human endothelial cells,
so they may be used for specific targeting of drugs to
the blood-brain barrier [171].
BECs are not only involved in transport/transcytosis of
peptides/proteins, but also as a target for various bioac-
tive peptides and in synthesis of neuroactive peptides. It
has been shown recently in a study on AVP-deficient
Brattleboro rats, that BECs produce and secrete several
chemokines after brain injury; this production is under
the synergistic control of AVP and TNF-a [172]. The
AVP effects were mediated by c-Jun N-terminal kinase
(JNK), a kinase that has increased activity in BECs in
response to injury [172].
Contrary to the situation at the BBB, several lines of
evidence indicate that members of the PTR family of
proton-coupled peptide transporters are expressed at
the BCSFB; this includes PEPT2, which is expressed in
the CP membranes [173] and PHT1 [174] (Figure 3B).
PEPT2 is a proton-coupled oligopeptide transporter and
it is abundant in epithelial layers, including kidney,
where it plays an important role in renal reabsorption of
di- and tri-peptides [138,175]. All evidence available so
far suggest that PEPT2 is located in the apical, CSF
-facing side, and it was responsible for 95% of dipeptide
(glycylsarcosine - GlySar) uptake by isolated CP that
was incubated in artificial CSF containing GlySar [173].
Wild-type mice had greater choroid plexus concentra-
tions of GlySar and a 5-fold greater CP/CSF ratio when
compared to PEPT2-null mice [175] and it was located
at the apical side of the rat CPE in primary culture
[176]. PEPT1 and PEPT2 have wide affinity for di-and
tripeptides with more than 8000 different substrates
identified so far [138]. Apart from CPE, in the CNS
PEPT2 is located in ependymal cells lining cerebral
ventricles [177]. Thus, the likely function of this trans-
porter is to clear di- and tri-peptides from the CSF. An
intense hybridization signal for PHT1 was found in the
brain, especially in the hippocampus and cerebellum,
while the signal in the CP was weaker [174]. PEPTs also
transport a number of peptidomimetics, so the presence
of this transporter at the apical membrane of the CPE
could severely restrict entry of blood-borne peptidomi-
metics into the CSF. The CPE is also involved in recep-
tor-mediated endocytosis of peptides. It has been shown
that transport of blood-born leptin to the CSF involves
leptin binding to LRP2 (megalin) in the CPE and trans-
cytosis of the LRP2/leptin complex through epithelial
cells [178]. The CPE also plays a role in clearance of Ab
from the CSF and it appears that LRP2 is involved in
this process, since it has been shown that AD patients
have reduced levels of LRP2 at the CP, which may
decrease efflux of Ab from the CSF and could be, there-
fore, one of the causes of increased brain levels of Ab
[179]. Another receptor belonging to the same LDL
receptor gene family appears also to be involved in Ab
clearance from the CSF: LRP1 is normally confined to
the CPE cytoplasm where it binds Ab; however, expo-
sure to lead causes protein kinase C-mediated relocation
of LRP1 and disrupts normal clearance of Ab from the
CSF, leading to its accumulation in the CPE [180].
The CPs are important not only in clearance of pep-
tides from the CSF and delivery of blood-borne peptides
to the CSF, but also as a target for a number of hor-
mones. Atrial natriuretic peptide (ANP) binds to its
receptors in the CPE, which generates cGMP; this sec-
ond messenger alters ion transport, thereby slowing CSF
production [181]. The presence of natriuretic peptide
receptor (NPR) A and NPR B, both containing a guany-
lyl-cyclase intracellular domain, was confirmed by
immunostaining in CPE, and also in some ependymal
cells in adult Sprague-Dawley rats [182]. Rats with con-
genital hydrocephalus had a lower number of binding
sites for radiolabelled ANP in the choroid plexus, as
compared to the control rats, indicating that this could
be one of the pathophysiological mechanisms underlying
excessive CSF production [183]. The CPE is also one of
the extra-hypothalamic sources of AVP [184]. The regu-
lation of choroidal AVP synthesis is similar to that
observed in the hypothalamus and it has been shown
that chronic hypernatremia increases the expression of
AVP in the CP [185]. It also appears that a well-known
inhibitory effect of centrally-released angiotensin II on
CSF production by the CPs is mediated by AVP produc-
tion in the CP and its paracrine action on V1 receptors
present in the CPE [186], which involves V1 receptor-
mediated decrease in Cl- efflux from epithelial cells
and consequent reduction in CSF formation [187].
An important role of CP-born bioactive peptides is
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proposed in brain recovery after traumatic brain injury
(TBI). It is believed that upregulated growth factors and
neurotrophins produced by the CPs and by the ependy-
mal layer are brought by the CSF bulk flow to brain
regions close to the ependymal layer and those factors
could be important for neural restoration through
enhanced neurogenesis and angiogenesis after TBI [188].
An important feature of CPE, that is not present in
the BECs, is a synthesis of transthyretin (TTR), which
functions as a carrier for thyroxin and retinol-binding
protein [189]. It also sequesters Ab peptide, and TTR
levels in the CSF appear to be inversely correlated with
Alzheimer’s disease (AD) onset and progression. TTR,
thyroxin-binding globulin (TBG) and albumin form a
“buffering” system for plasma L-thyroxin because of
their overlapping affinities for that hormone. CPs have
the highest concentration of transthyretin (TTR) mRNA
in the body and the percentage of TTR to total protein
synthesis in choroid plexus exceeds 10% [189]. However,
absence of TTR in genetically-modified mice did not
affect delivery of T4 to the brain [190]. 5-a-dihydrotes-
tosterone treatment increased TTR protein levels in
CPE cells in primary culture and induced TTR tran-
scription in these cells via an androgen receptor-inde-
pendent pathway [191]. On the other hand, treatment
with 17b-estradiol increased expression of TTR in CPs
in vivo at both transcript and protein levels via an oes-
trogen receptor a-dependent pathway [192,193]. Also,
expression of TTR both in vitro and in vivo was up-
regulated by treatment with progesterone, which
involves a progesterone receptor-mediated mechanism
[194]. These findings could at least partially explain
mechanisms involved in protective effects of progester-
one and estradiol against the onset of AD.
ABC-transporters, organic anion/cation transporters and
organic anion transporting polypeptide expression at the
BBB and the BCSFB
The family of ATP-binding cassette (ABC) transporters
is divided into subfamilies: the multidrug-resistance pro-
teins or P-glycoproteins (Abcb subfamily, HUGO names
ABCB1-11), the multidrug resistance-related proteins
MRPs (Abcc subfamily, HUGO names ABCC1-5) and
the breast cancer-resistance protein (BCRP, HUGO
names ABCG1-8) [195]. Their substrates range from
small ions to large polypeptides and transport occurs
against steep concentration gradients using energy that
is provided by ATP-hydrolysis [196]. Transport of
amphipathic molecules (i.e. organic anions) is sodium-
independent and mediate by transport proteins that
belong to two SCL families, the organic anion/cation
transporter family (OATs - SLC22) and the organic
anion transporting polypeptides family (OATPs -
SLC21). Members of the SLC21 family mediate
transport of large, amphipathic solutes such as bile salts,
thyroid hormones, leukotriene, and various steroids con-
jugates and xenobiotics [197]. OATs accept smaller and
more hydrophilic substrates than those carried by mem-
bers of the SLC21 family, including neurotransmitter
metabolites, cAMP, cGMP, and xenobiotics such as
para-aminohippuric acid, b-lactam and sulfonamide
antibiotics, non-steroidal anti-inflammatory drugs, anti-
viral drugs, antidiuretics, antiepileptics, methotrexate
[197]. Substrates for OCTs include neurotransmitters
(5-HT, dopamine), choline, tetraethylammonium ion,
cimetidine, N1-methylnicotinamide [198].
Given the mechanism of action of particular ABC
transporters, the precise localization of these proteins at
the BBB and BCSFB is essential for understanding their
role in physiology and in drug delivery to the brain. For
example, a luminally-located P-glycoprotein, which is
quantitatively the most important ABC transporter at
the BBB, would mediate efflux transport of its substrates
from the luminal membrane back to blood, which
would impede influx of substrates to the brain. On the
other hand, abluminally located P-gp would mediate
transport of substrates from the abluminal membrane
into the brain ISF, thereby facilitating influx of sub-
strates to the brain. In brain capillaries, P-gp is predo-
minantly and abundantly expressed in the luminal
membrane [199] and it mediates efflux of substrates
back into the blood after they initially diffuse into the
endothelial cell membrane (Figure 4A). By this action,
P-gp restricts penetration of its substrates into the
brain. A report has suggested that endothelial P-gp is
expressed at the nuclear membrane of rat brain micro-
vessel endothelial cell line RBE4 [200]. In rodents, two
multidrug resistance proteins are encoded by the genes
Mdr1a and Mdr1b and only Mdr1a is found in endothe-
lial cells [201]. Studies using P-gp knockout mice have
mainly contributed to the view of P-gp as the main gate-
keeper at the BBB [202]. Both SAGE analysis of the rat
BBB transcriptome and qPCR analysis of mouse BBB
transcriptome revealed that P-gp mRNA was highly
expressed in brain microvasculature [39,47]. The expres-
sion of MRPs is less clear and there are many conflict-
ing reports: some authors suggested that BECs express
multidrug resistance-associated protein Mrp1 (for the
review see [203]) at the luminal side, while others
revealed by immunofluorescence staining that this
protein is scarce at the BBB and localized abluminally
[199] (Figure 4A). However, MRP4, MRP5 and probably
MRP2 are located on the luminal membrane of
BECs (for reviews see [203,204]); MRP3 has only been
detected in capillaries from brain tumors [205]. Breast
cancer-resistance protein (BCRP, ABCG2) is expressed
at the luminal membrane of human BECs [206]
(Figure 4A) and its substrate specificity partially overlaps
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with that of P-gp. Data suggest that after P-gp, BCRP is
the second most abundant ABC transporter expressed
in human BECs [207]. In rodents, Oatp1a4 (Slc21a5, old
protein name Oatp2), Oatp1a5 (Slc21a7, old protein
name Oatp3) and Oatp1c1 (Slc21a14, old protein name
Oatp14) are expressed at blood-brain interfaces with
Oatp1a5 being located primarily abluminally and
Oatp1a4 on luminal and abluminal membranes
[126,203,208]. In humans OATP1A2 (SLC21A3, old
protein name OATP-A) and OATP2B1 (SLC21A9, old
protein name OATP-B) are localized at the luminal
membrane of BECs [209]. At the rodent BBB, Oat3
(Slc22a8) is predominantly localized at the abluminal
membrane [210], while OAT3 (SLC22A8) and OAT1
(SLC22A6) are found in epithelial cells of the human
CP [211], but their precise localization is not clear. Elec-
trogenic organic cation transporters (OCTs) are
expressed in rodent and human neurons and glial cells
and not in BECs in humans [212]. The proton gradient-
driven OCTN2 (SLC22A5), which mediates transport of
carnitine, is expressed in the abluminal membrane in
bovine BECs [213].
Many of those transporters have also been identified
in the CPs at the transcript or protein level or by func-
tional transport studies [214]. P-gp expression in the
human and rodent CP has been detected [215,216], but
other research groups have found P-gp in the CP to be
scarce or undetectable [217,218]. Studies that detected it
in the CP reported that P-gp was located at the apical
(CSF-facing) side and in sub-apical cell compartments
[216] (Figure 4B), which means that P-gp transports
substrates back into the CSF. So, the direction of P-gp-
mediated transport at the BCSFB appears to be opposite








Figure 4 Distribution of ABC-transporters, organic anion/cation transporters and organic anion transporting polypeptide expression in
the BECs (A) and in the CP epithelium (B). Members of the ABC family are presented in red, while SLC members are presented in various
tones of blue. Some data indicate that in the BECs Mrp1 and P-gp may also be present in organelles and nuclear envelope. Membrane
localization of Mrp1 in BECs is not completely clear, with some reports indicating that it is present at the luminal side, while others indicating
that it is scarce and probably located at the abluminal side. Mrp5 was detected in the CPE cells at the transcript level, but there are no
functional or immunocytochemical data so far, indicating its cellular localization (asterisk). The same stands for Oat2, Oct1-3 and Oatp9.
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transporter in the CP is Mrp1 (ABCC1) and it is located
basolaterally [216] (Figure 4B); MRP4 is also present in
the basolateral membrane of the human CPE cells [218].
Presence of mRNA for Mrp5 (ABCC5) in the CP has
also been revealed [219]. BCRP is located on the CSF
side of CPE cells in mice [220]. Cellular localization of
two Oatps in CP has been confirmed by immunochem-
ical studies: Oatp1a4, (Slc21a5, old protein name Oatp2)
is located at the basolateral membrane, while Oatp1a5
(Slc21a7, old protein name Oatp3) is located on the api-
cal membrane [221,222], with Oatp2 being probably the
most abundant Oapt in the CP [223]. Oatp2b1 (Slc21a9,
old protein name Oatp9) and Oatp1c1 (Slc21a14, old
protein name Oatp14) were detected in CP at the tran-
script and protein level; precise cellular localization of
Oatp9 is unknown [224], while Oatp14 appears to be
located primarily at the basolateral membrane (Figure
4B), and is involved in thyroid hormone transport [126].
Members of the Slc22a gene family, OAT1 (SLC22a6)
and OAT3 (SLC22a8) are located at the apical side of
the CPE [225], while expression of OAT2 mRNA in the
CP was confirmed but there are no data about cellular
localization [224]. The presence of Octs 1-3 has been
confirmed by RT-PCR but there are no further data on
their cellular localization.
Overall, the two important differences between the
BBB and the BCSFB with regard to expression of these
transporters are: P-gp is present at the blood-facing side
in the BECs and it is the most abundant transporter at
the BBB, while in the CP P-gp is expressed predomi-
nantly on the apical, CSF-facing side of the CPE cells
and it appears that the P-gp function in the CP is not
that critical for brain homeostasis, since the amount of
that protein in the CP is negligible (~0.5%) when com-
pared to its amount in BECs [217]. On the other hand,
at the BBB Mrp1 is fairly sparse while in CPE it is prob-
ably the most abundant transporter, exceeding by at
least 200-fold that in the BECs [217].
Since P-gp appears to be the main gatekeeper at the
BBB, a very important observation was that xenobiotics,
environmental toxins and pollutants, mediators of
inflammation and even the neurotransmitter glutamate
could affect expression of P-gp in the BECs, thereby
reducing or increasing drug delivery to the brain [213].
Briefly, exposure of rat BECs to xenobiotics or pollu-
tants that are ligands to androstane receptor (CAR) or
to pregnane-X receptor (PXR) causes activation of these
two receptors and then activated CAR/PXR translocate
to the nucleus to increase P-gp gene expression
[226,227]. A practical consequence of this mechanism is
that treatment with drugs that are P-gp substrates could
reduce delivery of other P-gp substrates to the brain.
Inflammatory signals have more complex effects on P-
gp expression: initially they cause a loss in P-gp activity
that is followed by delayed increase in activity and
expression [228]. Rapid and reversible loss of P-gp
transport function is not accompanied by change in pro-
tein expression and it involves binding of ligands
(endothelin - ET and tumor necrosis factor alpha -
TNFa) to toll-like receptor-4 (TLR4) or TNF-a receptor
1 (TNF-R1), which is followed by activation of nitric
oxide synthase (NOS) and protein kinase C (PKC). NOS
and PKC modify activity of the existing P-gp. Delayed
induction of P-gp expression includes signaling via
TNF-a [229] and ET-1, but in this case a signaling cas-
cade activates nuclear factor-B (NF-kB), which is a ubi-
quitous transcription factor that controls the expression
of genes; NF-kB then translocates to nucleus affecting
gene expression [230]. TNF-a-mediated signaling
includes not only an increase in expression of P-gp, but
also reduces the amount of Mrp2 and Mrp4 proteins
[229]. Also, it was revealed that diesel exhaust particles
(DEP) that can be found in polluted air could increase
expression of P-gp, Mrp1, Mrp2 and BCRP in BECs
[231]. The proposed mechanism involves TNF-a signal-
ing, which means that chronic exposure to DEPs could
cause additional oxidative and inflammatory stress for
the brain; this corresponds to finding that DEPs induce
inflammatory responses in microglia [232].
Another challenging area for ABC transporter
research is a hypothesis that their failure could be asso-
ciated with Alzheimer’s disease (AD) where P-gp and
Bcrp could serve as efflux pumps for b-amyloid peptide
[233,234]. The existing reports are conflicting: it has
been revealed that brain capillaries of Alzheimer’s
patients have reduced expression of P-gp [235] and
increased expression of BCRP [234]; however, a recent
study by confocal microscopy that quantified peak fluor-
escence values of cross-sectional profiles of brain micro-
vessels, revealed expression of P-gp protein to be
significantly lower in hippocampal vessels of patients
with AD compared to normal individuals, whereas that
of MRP4 or BCRP protein was not changed [236]. How-
ever, the same study reported that analysis of the sec-
tions at protein level via Western blotting or at
transcript level by qPCR did not reveal significantly
lower expression for either P-gp or BCRP [236].
Ion transporters in the BBB and CP
There is evidence suggesting that there is a bulk flow of
the brain ISF from brain capillaries towards the ventri-
cular space and that ISF merges with the CSF; this flow
takes place predominantly along perivascular spaces (for
a review see [237]). This indicates that there is a con-
stant production of a “new” ISF in the brain which con-
tributes to total volume of the CSF. Although some of
the ISF is probably generated from water produced by
brain metabolism, fluid secretion by BECs appears to be
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an important source of this ISF [237], accounting for at
least 30% of the ISF production [238]. This process is
essential for maintaining correct fluid balance in the
brain. Two membrane proteins that work simulta-
neously but at different membranes of the BECs are key
regulators of net sodium and chloride transport across
the BBB: Na+, K+-ATPases (ATP1 family) and the Na+,
K+, 2Cl-cotransporter (SLC12 family). The Na+, K
+-ATPase is localized on the abluminal membrane and
provides a driving force for the net ion and water move-
ment across the BBB [239] (Figure 5A); 3 alpha-
(ATP1A1-3) and 2 beta- (ATP1B1-2) subunit isoforms
were found in rat BECs, which means that six structu-
rally distinct Na+, K+-ATPase isoenzymes are likely to
be expressed in brain microvessels [240]. As in other tis-
sues, the activity of this enzyme is tightly associated
with cell volume regulation [241]. The Na+-K+-2Cl--
cotransporter is located at the luminal side of BECs
[242] and its activity is regulated by PKC signalling
[243]. In addition, rat brain endothelial cells express Kv1
and Kir2 potassium channels; these are probably located
on both the luminal and abluminal sides of the BECs
[244] (Figure 5A). Furthermore, BECs also express two
ion exchangers that belong to the SLC family and are
probably involved in intracellular pH regulation: chlor-
ide-bicarbonate (Cl-, HCO3
--) exchanger (SLC4A1) and
sodium-hydrogen (Na+, H+-) exchanger (SLC4A6). Both
isoforms of Na+, H+-exchanger (Nhe1 and Nhe2) are
expressed on the luminal membrane, whereas chloride-
bicarbonate exchanger(Ae1) is expressed at both luminal
and abluminal membranes of the BECs (Figure 5A)
[245]. Net flux of K+ at the BBB is critical for brain
homeostasis, since changes in concentration affect rest-
ing membrane potential; however, net flux of this ion
across the BBB is not well understood. Both Na+, K
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Figure 5 Distribution of ion transporters and channels in the BECs (A) and in the CP epithelium (B). Only those transporters and channels
that play a role in vectorial transport of Na+, Cl-, HCO3
- and K+ are shown. These include Na+, K+-ATPase, potassium channels Kir and Kv,
chloride/bicarbonate channel Clir and members of the SLC: Na+, HCO3
- cotransporters 1 and 2 (NBCn1 and 2), Cl-, HCO3
- exchangers 1 and 2 (Ae
1 (in the BBB, figure A) and Ae2 (in the CP, figure B), Na+, H+ exchanger 1 and 2 (Nhe1 and Nhe2), K+-Cl–cotransporters 3 and 4 (KCC3 and 4, in
the CP, figure B), Na+-K+-2Cl- cotransporter 1 (NKCC1, in the BBB, figure A) and electrogenic Na+, HCO3
- exchanger (NBCe2, in the CP, figure B). In
addition, localization of two carbonic anhydrase isoenzymes in the CP epithelium (figure B), CA2 and CA12 are shown, as well as localization of
aquaporin 1 (AQP1). Symbol * indicates that NBCn1 was detected in CPE, but it probably does not play a role in vectorial transport of these two
ions.
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ion into the BECs and at least two potassium channels
exist on both sides (Figure 5A). A hypothesis suggested
that there was a net K+ efflux across the BBB, which
contributed to low K+ concentration in the brain ISF
[246]. However, the CSF recovered from the brain, con-
tains 2.5-3.0 mM K+ and the CSF originates either from
CP secretion or from the brain ISF, although the relative
contribution of those two sources is a matter of debate.
Thus, at least one of these two (CSF secreted by the
CPS or brain ISF secreted by the BECs) have to be a
source of K+ in the CSF. CPs in fact mainly reabsorb K+
from the CSF (see below). Thus, bearing in mind con-
servation of mass, a speculation could also be made that
K+ found in the CSF is, at least partially, K+ that was
secreted at the BBB.
Ion transport at the BBB also plays an important role in
regulation of endothelial cell pH, especially bicarbonate
transport driven by Cl-, HCO3
- -exchanger and H+ trans-
port driven by Na+, H+ -exchanger. It has been shown
that following in vitro loading of BECs with small acid
load, HCO3
- influx was mainly responsible for the acid
extrusion and it was mediated partially by Cl- dependent
HCO3
- transporters. However, after large acid loads,
BECs removed acid almost solely by Na+, H+ exchange,
with the rate of its activity depending linearly on intracel-
lular pH [247]. Following an alkaline load to BECs, the
intracellular pH was restored by acid loading which
occurred via Cl-/HCO3
- exchange [247].
Ion transporters in the CPs have been studied inten-
sively because ion transport across the CPE drives CSF
secretion, which could be considered as the most appar-
ent and the most important function of CPs. CSF has a
number of important roles in brain homeostasis, includ-
ing reduction of the effective weight of the brain by
being submerged in CSF, removal of waste products of
metabolism, removing excess neurotransmitters and
debris from the surface lining epithelium and delivering
signalling molecules (for a review of CSF functions see
[248]). Bicarbonate transport by the CPE directly affects
the pH of CSF, which in turn affects neuronal activity in
the respiratory centre in the medulla oblongata.
Overall, two main processes are driven by ion transpor-
ters in the CP. First, the transepithelial basolateral-to-
CSF movement of sodium, bicarbonate and chloride cre-
ates a small osmotic force driving net movement of water
in the same direction. Water movement across the CPE
is via aquaporin 1, the waater channel which is abun-
dantly expressed in the apical membrane and less so in
the basolateral membrane (Figure 5B). This water chan-
nel is typical for epithelia that have a high rate of water
transfer generated by a small osmotic gradient. Second,
CSF to basolateral movement of potassium takes place
[249,250]. However, it should be remembered that there
are net fluxes of other ions across the CPE: Ca2+, organic
anions and cations.
Although it would be possible for Na+ to diffuse
through paracellular spaces in the CPE (taking into
account that TJs in the CP epithelium are relatively
“leaky” due to the expression of certain claudins), analy-
sis of electrochemical relations between the plasma and
the CSF reveals that a gradient created by a CSF lumen-
positive transepithelial voltage, which impedes Na+ dif-
fusion towards the CSF, exceeds the blood-to-ventricle
chemical gradient for Na+; thus, the net movement of
Na+ from the blood side to the ventricle has to be an
active ATP-dependent process [250]. Ion transporters
expressed on the basolateral side of the CP epithelium
load cells with Na+, while ion transporters expressed at
the apical (CSF) side transport Na+ from cells into the
CSF. Two major anions, Cl- and HCO3
- also pass the
CPE layer via a transcellular route; the CSF concentra-
tions of both Cl- and HCO3
- are less than predicted for
simple diffusion, which suggests that the paracellular
route contributes negligibly to the overall transfer.
It is believed that the main entry route for Na+ at the
basolateral membrane is a stilbene-sensitive Na+-
HCO3
- transporter (SLC4A10 or NBCn2/NBCE) (Figure
5B). This transporter was also known as Na+- dependent
Cl-/HCO3
- exchanger, but the reported dependence of
this transporter on intracellular Cl- has been disputed
and the transporter was characterized as an electroneu-
tral Na+ - HCO3
- cotransporter [251]. In the CP, this
transporter is expressed only in the basolateral mem-
brane and transports Na+ and HCO3
- into the cell [251].
Mice that had this transporter genetically removed had
severe reduction in brain ventricle size, which suggested
that the rate of CSF secretion was decreased [252]. This
transporter is also important for loading CPE cells with
HCO3
-. The Na+, HCO3- cotransporter 1 (SLC4A7 or
NBCn1) is also expressed in the CPE basolateral mem-
brane [251] (Figure 5B), but evidence suggests that it
does not play a major role in basolateral Na+ loading
and vectorial flux of this ion [250]. Cl- accumulates in
the CPE by action of the Cl-, HCO3
- -exchanger (anion
exchange protein 2, SLC4A2 or Ae2) [253]. In the CPE,
Cl- movement intracellularly is driven by an outwardly-
directed transmembrane gradient for HCO3
- that is cre-
ated by the basolateral Na+, HCO3
- -cotransport [250].
Transport of these ions through the apical membrane
to the CSF involves several proteins. Na+, K+- ATPase,
which in the CPE is located exclusively in the apical
membrane, is probably the most important Na+ extruder
[253] (Figure 5B). Three Na+, K+-ATPase subunits are
expressed in CP epithelium at the transcript level:
a1 (ATP1A1), b1 (ATP1B1) and b2 (ATP1B2) [240].
The Na+, H+-exchanger 1 (SLC9A1 or Nhe1) has also a
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predominantly apical localization in the CPE [212]; how-
ever, it is involved in intracellular pH regulation rather
than in extrusion of Na+ and it has been shown that Na
+, H+-exchanger 1 knockout mouse lacked Na+-depen-
dent intracellular pH recovery following acidification of
CPE cells [254].
Transport of Cl- across apical side is driven by a gra-
dient towards the CSF and takes place mainly via K+-Cl-
-cotransporter 4 (SLC12A7 or KCC4), that is expressed
on the apical side (Figure 5B). The apical side also
expresses the Na+-K+-2Cl-- cotransporter 1 (SLC12A2
or NKCC1) [255], but its contribution to overall ion flux
in this tissue is controversial because the net driving
force for this transporter is close to zero due to high
intracellular Na+ and Cl- and low K+ in the CSF [255],
A recent report suggested that this transporter does not
contribute to net ion fluxes [256]. Bicarbonate transport
to the CSF across the apical surface is mediated mainly
by the electrogenic Na+, HCO3
- -exchanger (SLC4A5 or
NBCe2/NBC4) that couples transport of 1 Na+ with 3
HCO3
- and has an important role in CSF pH regulation
[244]. In amphibian CP HCO3
- flux across the apical
membrane is mainly via Cl- ion channel that has high per-
meability for HCO3
- [6]. This channel (Clir) plays some
role in apical HCO3
- extrusion in mammals, but perme-
ability of this channel for HCO3
- appears to be small.
It should be stressed that this section has focused only
on molecular biology of transport for the principal ions:
Na+, K+, Cl- and HCO3
- and that it has not covered the




Studies of the past two decades have provided insight
into the molecular biology which underlines function of
the two most important blood-brain fluid interfaces, the
BBB and the BCSFB. Efficient homeostatic mechanisms
established by those two barriers control composition of
brain extracellular fluids, the ISF and CSF. These are
vital to normal neuronal function and signal processing
in the CNS. Two obvious functions that are common to
the BBB and the BCSFB are the restriction of free diffu-
sion and the transport of nutrients, waste products, sig-
nalling molecules and ions between blood and brain
extracellular fluids. However, those two structures show
important differences in their respective roles that are
underlined by differences in expression of cell junction
proteins, transport proteins and ion channels. An
important similarity between the two barriers is that
they are both dynamic systems and are able to respond
rapidly to changes in brain requirements. The molecular
basis of this feature is that the BBB and the BCSFB
could be regulated via a number of molecular mechan-
isms under normal physiological or pathological
conditions. Further insights into molecular mechanisms
involved in BBB and BCSFB regulation should provide
molecular cues for targeting the brain barriers in CNS
diseases.
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